We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zimmer Biomet Q3 Earnings Top but Revenue Miss Causes Pre-Market Drop
Read MoreHide Full Article
Key Takeaways
Zimmer Biomet's Q3 adjusted EPS rose 9.2% year over year, topping the consensus estimate.
Revenues grew 9.7% to $2.00B but missed expectations due to weakness in Knees and Hips.
The company reaffirmed EPS guidance but narrowed its revenue growth outlook for 2025.
Zimmer Biomet Holdings, Inc. (ZBH - Free Report) posted third-quarter 2025 adjusted earnings per share (EPS) of $1.90, which beat the Zacks Consensus Estimate by 1.06%. The adjusted figure rose 9.2% year over year.
The quarter’s adjustments included certain amortization, restructuring and other cost reduction initiatives, inventory and manufacturing-related charges and European Union Medical Device Regulation-related charges, among others.
On a reported basis, the company registered earnings of $1.16 per share compared with $1.23 in the year-ago period.
However, following the announcement, shares of ZBH declined 8.1% in pre-market trading today.
ZBH's Q3 Revenues
Third-quarter net sales of $2.00 billion increased 9.7% (up 8.6% at constant exchange rate or CER) year over year. The figure missed the Zacks Consensus Estimate by 0.4%.
ZBH's Revenues by Geography
During the third quarter, sales generated in the United States totaled $1.16 billion (up 10.6% year over year), while International sales grossed $837.3 million (up 8.5% year over year on a reported basis and 5.9% at CER).
Our model projected revenues of $1.16 billion from the United States and $834 million from International.
Zimmer Biomet Holdings, Inc. Price, Consensus and EPS Surprise
The company currently reports under four product categories — Knees, Hips, S.E.T. (Sports Medicine, Extremities, Trauma, Craniomaxillofacial and Thoracic) and Technology & Data, Bone Cement and Surgical.
Sales in the Knees unit improved 5.3% year over year at CER to $792.4 million. Our model estimate was pegged at $820.5 million.
Hipssales grew 3.8% year over year at CER to $506.2 million. Our model estimate was $512.2 million for the same.
Revenues in the S.E.T. unit rose 18.2% year over year at CER to $541.5 million. Our model estimate was $498.3 million.
Technology & Data, Bone Cement and Surgical(historically referred to as "Other") revenues rose 11.3% to $161.3 million at CER in the third quarter. Our model estimate was $166.5 million.
ZBH's Margin Performance
Adjusted gross margin, after excluding the impact of intangible asset amortization, was 72.1%, an expansion of 158 basis points (bps) year over year. Selling, general and administrative expenses rose 14.3% to $811.4 million. Research and development expenses rose 3.9% to $115.9 million. Adjusted operating margin expanded 27 bps to 25.7%.
ZBH's Cash Position
Zimmer Biomet exited the third quarter with cash and cash equivalents of $1.29 billion compared with $525.5 million at the end of the second quarter of 2025.
Cumulative net cash provided by operating activities at the end of the third quarter was $1.18 billion compared with $993.1 million in the year-ago period.
ZBH’s Updated 2025 Outlook
Zimmer Biomet updated its financial guidance for 2025.
Reported revenue growth guidance was reiterated in the band of 6.7-7.7%. The upper limit of 2025 constant currency revenue growth was reduced. The new range is 6.2% - 6.7% (earlier range was 6.2% - 7.2%). The Zacks Consensus Estimate for revenues is pegged at $8.22 billion.
Adjusted EPS guidance for the full year was reiterated in the range of $8.10-$8.30.
The Zacks Consensus Estimate for 2025 adjusted EPS is pegged at $7.95.
Our Take on ZBH
Despite third-quarter 2025 adjusted EPS beating the Zacks Consensus Estimate and margin expansion, investors were likely disappointed by the overall performance, which was evident in the share price performance. Zimmer Biomet missed the Zacks Consensus Estimate on revenues and posted softer-than-expected performance in key categories like Knees and Hips (going by Zacks expectations). Further, while management reiterated full-year EPS guidance, the company trimmed the upper end of its constant-currency revenue growth outlook, signaling a more cautious demand environment ahead.
ZBH's Zacks Rank and Key Picks
Zimmer Biomet currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Medpace Holdings (MEDP - Free Report) , IDEXX Laboratories (IDXX - Free Report) and Boston Scientific (BSX - Free Report) .
Medpace, currently sporting a Zacks Rank #1 (Strong Buy), reported third-quarter 2025 EPS of $3.86, which surpassed the Zacks Consensus Estimate by 10.29%. Revenues of $659.9 million beat the Zacks Consensus Estimate by 3.04%. You can see the complete list of today’s Zacks #1 Rank stocks here.
MEDP has an estimated earnings growth rate of 17.1% for 2025 compared with the industry’s 16.6% growth. The company beat on earnings in each of the trailing four quarters, the average surprise being 14.28%.
IDEXX, carrying a Zacks Rank #2 (Buy) at present, posted third-quarter 2025 adjusted EPS of $3.40, which exceeded the Zacks Consensus Estimate by 8.3%. Revenues of $1.11 billion topped the Zacks Consensus Estimate by 3.2%.
IDXX has an estimated historical earnings growth rate of 14.9% compared with the industry’s 10.1% growth. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 6.08%.
Boston Scientific, currently carrying a Zacks Rank #2, reported third-quarter 2025 adjusted EPS of 75 cents, which surpassed the Zacks Consensus Estimate by 5.6%. Revenues of $5.07 billion topped the Zacks Consensus Estimate by 1.9%.
BSX has an estimated long-term earnings growth rate of 16.4% compared with the industry’s 13.5% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 7.36%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Zimmer Biomet Q3 Earnings Top but Revenue Miss Causes Pre-Market Drop
Key Takeaways
Zimmer Biomet Holdings, Inc. (ZBH - Free Report) posted third-quarter 2025 adjusted earnings per share (EPS) of $1.90, which beat the Zacks Consensus Estimate by 1.06%. The adjusted figure rose 9.2% year over year.
The quarter’s adjustments included certain amortization, restructuring and other cost reduction initiatives, inventory and manufacturing-related charges and European Union Medical Device Regulation-related charges, among others.
On a reported basis, the company registered earnings of $1.16 per share compared with $1.23 in the year-ago period.
However, following the announcement, shares of ZBH declined 8.1% in pre-market trading today.
ZBH's Q3 Revenues
Third-quarter net sales of $2.00 billion increased 9.7% (up 8.6% at constant exchange rate or CER) year over year. The figure missed the Zacks Consensus Estimate by 0.4%.
ZBH's Revenues by Geography
During the third quarter, sales generated in the United States totaled $1.16 billion (up 10.6% year over year), while International sales grossed $837.3 million (up 8.5% year over year on a reported basis and 5.9% at CER).
Our model projected revenues of $1.16 billion from the United States and $834 million from International.
Zimmer Biomet Holdings, Inc. Price, Consensus and EPS Surprise
Zimmer Biomet Holdings, Inc. price-consensus-eps-surprise-chart | Zimmer Biomet Holdings, Inc. Quote
Segmental Analysis of ZBH's Revenues
The company currently reports under four product categories — Knees, Hips, S.E.T. (Sports Medicine, Extremities, Trauma, Craniomaxillofacial and Thoracic) and Technology & Data, Bone Cement and Surgical.
Sales in the Knees unit improved 5.3% year over year at CER to $792.4 million. Our model estimate was pegged at $820.5 million.
Hipssales grew 3.8% year over year at CER to $506.2 million. Our model estimate was $512.2 million for the same.
Revenues in the S.E.T. unit rose 18.2% year over year at CER to $541.5 million. Our model estimate was $498.3 million.
Technology & Data, Bone Cement and Surgical(historically referred to as "Other") revenues rose 11.3% to $161.3 million at CER in the third quarter. Our model estimate was $166.5 million.
ZBH's Margin Performance
Adjusted gross margin, after excluding the impact of intangible asset amortization, was 72.1%, an expansion of 158 basis points (bps) year over year. Selling, general and administrative expenses rose 14.3% to $811.4 million. Research and development expenses rose 3.9% to $115.9 million. Adjusted operating margin expanded 27 bps to 25.7%.
ZBH's Cash Position
Zimmer Biomet exited the third quarter with cash and cash equivalents of $1.29 billion compared with $525.5 million at the end of the second quarter of 2025.
Cumulative net cash provided by operating activities at the end of the third quarter was $1.18 billion compared with $993.1 million in the year-ago period.
ZBH’s Updated 2025 Outlook
Zimmer Biomet updated its financial guidance for 2025.
Reported revenue growth guidance was reiterated in the band of 6.7-7.7%. The upper limit of 2025 constant currency revenue growth was reduced. The new range is 6.2% - 6.7% (earlier range was 6.2% - 7.2%). The Zacks Consensus Estimate for revenues is pegged at $8.22 billion.
Adjusted EPS guidance for the full year was reiterated in the range of $8.10-$8.30.
The Zacks Consensus Estimate for 2025 adjusted EPS is pegged at $7.95.
Our Take on ZBH
Despite third-quarter 2025 adjusted EPS beating the Zacks Consensus Estimate and margin expansion, investors were likely disappointed by the overall performance, which was evident in the share price performance. Zimmer Biomet missed the Zacks Consensus Estimate on revenues and posted softer-than-expected performance in key categories like Knees and Hips (going by Zacks expectations). Further, while management reiterated full-year EPS guidance, the company trimmed the upper end of its constant-currency revenue growth outlook, signaling a more cautious demand environment ahead.
ZBH's Zacks Rank and Key Picks
Zimmer Biomet currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Medpace Holdings (MEDP - Free Report) , IDEXX Laboratories (IDXX - Free Report) and Boston Scientific (BSX - Free Report) .
Medpace, currently sporting a Zacks Rank #1 (Strong Buy), reported third-quarter 2025 EPS of $3.86, which surpassed the Zacks Consensus Estimate by 10.29%. Revenues of $659.9 million beat the Zacks Consensus Estimate by 3.04%. You can see the complete list of today’s Zacks #1 Rank stocks here.
MEDP has an estimated earnings growth rate of 17.1% for 2025 compared with the industry’s 16.6% growth. The company beat on earnings in each of the trailing four quarters, the average surprise being 14.28%.
IDEXX, carrying a Zacks Rank #2 (Buy) at present, posted third-quarter 2025 adjusted EPS of $3.40, which exceeded the Zacks Consensus Estimate by 8.3%. Revenues of $1.11 billion topped the Zacks Consensus Estimate by 3.2%.
IDXX has an estimated historical earnings growth rate of 14.9% compared with the industry’s 10.1% growth. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 6.08%.
Boston Scientific, currently carrying a Zacks Rank #2, reported third-quarter 2025 adjusted EPS of 75 cents, which surpassed the Zacks Consensus Estimate by 5.6%. Revenues of $5.07 billion topped the Zacks Consensus Estimate by 1.9%.
BSX has an estimated long-term earnings growth rate of 16.4% compared with the industry’s 13.5% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 7.36%.